CD103 ImmunoPET is a promising method for determining tumor-infiltrating lymphocytes (TILs) load and response to ICIs, thereby addressing the lack of reliable biomarkers in cancer immunotherapy. Compared to general T cell markers, CD103 is a specific marker for tissue-resident memory T cells, which number increases during successful ICI therapy. ImmunoPET offers noninvasive, dynamic imaging of specific markers, complemented by detailed molecular information from immunohistochemistry (IHC). Radiomics can extract quantitative features from traditional imaging methods, while near-infrared fluorescence (NIRF) imaging aids tumor detection during surgery. In the era of precision medicine, combining such methods will offer a more comprehensive approach to cancer diagnosis and treatment.
Keyphrases
- high resolution
- minimally invasive
- working memory
- patient safety
- healthcare
- nk cells
- quality improvement
- oxidative stress
- magnetic resonance imaging
- single molecule
- mass spectrometry
- magnetic resonance
- mesenchymal stem cells
- lymph node metastasis
- coronary artery bypass
- percutaneous coronary intervention
- childhood cancer
- photodynamic therapy
- energy transfer